Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | DGKA | P23743 | 1/20 | 0.52 |
| ▸ | CASP2 | P42575 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 3/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6898417 | 0.88 | CYP3A4 (0.58) | L3MBTL1MAPTSMN1; SMN2CASP2FAAH | |
| SCHEMBL7155471 | 0.87 | DGKA (0.62) | L3MBTL1EPHX2DGKACASP2FAAH | |
| SCHEMBL21467745 | 0.83 | L3MBTL1 (0.65) | L3MBTL1EPHX2DGKACASP2FAAH | |
| SCHEMBL21468101 | 0.83 | L3MBTL1 (0.65) | L3MBTL1EPHX2DGKACASP2FAAH | |
| SCHEMBL7724543 | 0.83 | L3MBTL1 (0.65) | L3MBTL1EPHX2DGKACASP2FAAH | |
| SCHEMBL23599312 | 0.83 | L3MBTL1 (0.65) | L3MBTL1EPHX2DGKACASP2FAAH | |
| SCHEMBL21468095 | 0.83 | L3MBTL1 (0.65) | L3MBTL1EPHX2DGKACASP2FAAH | |
| SCHEMBL20903685 | 0.83 | L3MBTL1 (0.65) | L3MBTL1EPHX2DGKACASP2FAAH | |
| SCHEMBL7737177 | 0.83 | L3MBTL1 (0.65) | L3MBTL1EPHX2DGKACASP2FAAH | |
| SCHEMBL9801606 | 0.83 | L3MBTL1 (0.65) | L3MBTL1EPHX2DGKACASP2FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4124616-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | Alkermes Pharma Ireland Limited (IE) | 2023-02-01 | — | — | EP | disclosed |
| EP-2445502-B2 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | ALKERMES PHARMA IRELAND LTD (IE) | 2022-09-28 | — | — | EP | disclosed |
| US-10351529-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | ALKERMES PHARMA IRELAND LIMITED (IE) | 2019-07-16 | — | — | US | disclosed |
| US-20190084937-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2019-03-21 | — | — | US | disclosed |
| EP-3309151-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | Alkermes Pharma Ireland Limited (IE) | 2018-04-18 | — | — | EP | disclosed |
| EP-2445502-B1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | ALKERMES PHARMA IRELAND LTD (IE) | 2017-06-21 | — | — | EP | disclosed |
| US-20170015659-A1 | Prodrugs of NH-Acidic Compounds | JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT | 2017-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170015659-A1 | Prodrugs of NH-Acidic Compounds | SI, NAAA, NIT2 | L3MBTL1 4382/4885MAPT 2880/4885EPHX2 736/4885 |
| US-20190084937-A1 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | GABBR1, GABBR2, GABRE | L3MBTL1 3121/4885MAPT 165/4885EPHX2 3077/4885 |
| US-10351529-B2 | Heterocyclic compounds for the treatment of neurological and psychological disorders | GABBR1, GABBR2, GABRE | L3MBTL1 3121/4885MAPT 165/4885EPHX2 3077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.